TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12137873
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d)
Study: 29424236
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention (up to 10 sessions based on cognitive behavioural therapy) plus usual care
Study: 22114787
Drug: Vitamin D3‐fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3‐fortified yogurt drink (FYD; containing 170 mg calcium and 500 IU/250 mL)
Study: 22114787
Drug: Plain yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain yogurt drink (PYD; containing 170 mg calcium and no vitamin D/250 mL)
Study: 16464371
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (medication and traditional acupuncture treatment)
Study: 11131819
Drug: Non-evaluated solutions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-evaluated solutions
Study: 11918735
Drug: 40 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol/L lactate dialysate
Study: 9068022
Drug: 38 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 mmol/L bicarbonate fluid
Study: 9068022
Drug: 25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate
Study: 7877434
Drug: Alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha interferon treatment
Study: 7814812
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alpha interferon (≤ 200 MU/m2)
Study: 7814812
Drug: Medium/high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium/high dose alpha interferon (≥ 200 MU/m2)
Study: 2690545
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g cholestyramine
Study: 1099036
Drug: 30% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% sodium thiosulfate application, ultraviolet light, and meladinine tablets (amoidin 0.01 g and amidin 0.005 g)
Study: 26829647
Drug: 30 or
Normalized name: Oseni 25/30 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 or 60 mg gevokizumab every 4 weeks intravenously or subcutaneously
Study: 20713437
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (CST)
Study: 18589556
Drug: Epoetin zeta
Normalized name: Epoetin zeta
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin zeta (10,000 IU, subcutaneous injection)
Study: 18589556
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (10,000 IU, subcutaneous injection)
Study: 16583597
Drug: Whitening lamp
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening lamp and peroxide gel (20% hydrogen peroxide)
Study: 16583597
Drug: No light
Normalized name: OCTINOXATE 67 mg in 1 mL / TITANIUM DIOXIDE 18 mg in 1 mL TOPICAL LOTION [Valentino Very Valentino Light Lasting Perfecting Foundation Broad Spectrum SPF 26 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No light treatment with peroxide gel (20% hydrogen peroxide)
Study: 11854731
Drug: Synthetic patches
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic patches
Study: 7633717
Drug: Inhaled indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled indomethacin (3 mg/m2 body-surface area)
Study: 7633717
Drug: Inhaled indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled indomethacin
Study: 2653057
Drug: Carbamazepine, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine, 800 mg/day
Study: 2653057
Drug: Oxazepam, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam, 120 mg/day
Study: 71396
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated measles vaccine (Schwarz strain)
Study: 19117865
Drug: Lucinactant 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucinactant 90 mg/kg
Study: 19117865
Drug: Lucinactant 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucinactant 175 mg/kg
Study: 16532712
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers (ARB)
Study: 15017527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ARB and ACE inhibition
Study: 9233053
Drug: Sumatriptan (SU)
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan (SU) 6 mg s.c.
Study: 2877129
Drug: Synvinolin (MK-733)
Normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synvinolin (MK-733) 2.5 mg/day
Study: 2877129
Drug: Synvinolin (MK-733)
Normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synvinolin (MK-733) 80 mg/day
Study: 2877129
Drug: Synvinolin (MK-733)
Normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synvinolin (MK-733) (doses ranging from 2.5 mg to 80 mg per day)
Study: 18226766
Drug: Furosemide (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (intravenous diuretics)
Study: 12589153
Drug: Clodronate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1600 mg/day in two divided doses)
Study: 8668962
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 1 g of IgG in 10 ml saline
Study: 8668962
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 10 ml physiological saline
Study: 1844697
Drug: Two formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two formulations
Study: 30106172
Drug: Galcanezumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (120 mg subcutaneous injection)
Study: 23176889
Drug: Subcutaneous allergy
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergy immunotherapy
Study: 19254374
Drug: Trial design
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial design barriers, lack of access to treatment, individual barriers of recruiting physicians, insufficient training of recruiting physicians
Study: 17966072
Drug: Aluminum (Amphojel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum (Amphojel plus citrate) administered orally for 3 days followed by a 3-week washout, then matched placebo for 3 days.
Study: 17966072
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 3 days after aluminum treatment.
Study: 11556665
Drug: Vestibular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular therapy post-therapy.
Study: 10074720
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous immunoglobulin (IVIG) therapy, 750-1000 mg/kg for infants <1000 g, 500-750 mg/kg for infants 1001-1500 g, administered every 2 weeks until 1800 g or discharge
Study: 10074720
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received saline infusion, administered every 2 weeks until 1800 g or discharge
Study: 7839076
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone pulse therapy (100 mg in 250 ml 5% dextrose infused over 1 h, repeated every month for 6 months)
Study: 7839076
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone pulse therapy
Study: 3060542
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream applied five times daily for 5 days
Study: 27478849
Drug: Topical pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical pirfenidone plus conventional treatment
Study: 23051740
Drug: High-dose angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose angiotensin II receptor blocker (ARB)
Study: 24599010
Drug: ARB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB plus calcium channel blocker (CCB)
Study: 20674497
Drug: Metabolic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic therapy (coenzyme Q(10), magnesium orotate, lipoic acid, omega‐3 fatty acids and selenium)
Study: 12452233
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of EMLA cream
Study: 12452233
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 1% lidocaine
Study: 12452233
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 2% lidocaine
Study: 10592355
Drug: Twice-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly hemodialysis
Study: 10592355
Drug: Thrice-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly hemodialysis
Study: 2430606
Drug: Atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.6 mg kg‐1
Study: 1962902
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (FR‐860) at 75 U/kg/day in group I (n = 27)
Study: 1962902
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (FR‐860) at 150 U/kg/day in group II (n = 29)
Study: 6273027
Drug: 1,25(OH)2D3 (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (mean dose 0.5 microgram daily)
Study: 6273027
Drug: D3 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 (dose 100 microgram daily)
Study: 25599449
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement (5 g of transdermal gel daily for 14 weeks)
Study: 24073230
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire modes
Study: 24073230
Drug: Interviewer-administered questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered questionnaire mode
Study: 24073230
Drug: Self-administered modes
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered modes (when completed twice)
Study: 21416219
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid 135 mg added to moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 52 weeks
Study: 21416219
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid with moderate-dose statin
Study: 8916520
Drug: Nurse-managed smoking
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-managed smoking cessation program including a meeting with the nurse-case manager, videotape, workbook, relaxation audiotape, nicotine replacement therapy, and nurse-initiated phone contacts after discharge
Study: 23351426
Drug: Adverse information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse information on the risks of the combined oral pill
Study: 23351426
Drug: Promotional material
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotional material on the vaginal ring and transdermal patch
Study: 16730732
Drug: THD 1g
Normalized name: THD-DP-FM
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THD 1g daily
Study: 11936564
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg q 12 h
Study: 11936564
Drug: Voriconazole 300
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 300 mg q 12 h
Study: 11936564
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg OD
Study: 7703619
Drug: Calcium absorption
Normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium absorption (net and true) measured in 18-day balances and by a two-isotope deconvolution method (fractional absorption and maximum absorption rate, MAR)
Study: 1668825
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant chemotherapy alone
Study: 7073151
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg four times daily for 1 day
Study: 31362765
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 1-g loading dose followed by 3-g maintenance dose over 24 hours
Study: 24703047
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg once weekly titrated to 50 mg at week 6
Study: 24703047
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg once daily titrated to 1.2 mg at week 1 and 1.8 mg at week 2
Study: 22245322
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (placebo group)
Study: 18951459
Drug: Yale-Brown-Cornell Eating
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) pre- and post-treatment
Study: 15678733
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 15 microg kg(‐1) h(‐1)
Study: 15678733
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion 60 microg kg(‐1) h(‐1)
Study: 12080408
Drug: Multi-micronutrient supplementation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient supplementation (daily tablet containing 1000 microg vitamin A)
Study: 12080408
Drug: Multi-helminth chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-helminth chemotherapy (single treatment with albendazole 600 mg and praziquantel 40 mg/kg)
Study: 26581683
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea extract (GTE) 1315 mg total catechins/d
Study: 26581683
Drug: COMT high-activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMT high-activity (G/G) genotype
Study: 22497967
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR) 3000mg once daily (G-GR-QD)
Study: 22497967
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR) divided dose (G-GR-DD, 1200mg AM/1800mg PM)
Study: 18539989
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 or 2.5 mg
Study: 12917299
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin therapy (target INR of 1.5 to 1.9)
Study: 12917299
Drug: Conventional-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-intensity warfarin therapy (target INR of 2.0 to 3.0)
Study: 10622270
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment (0.5-2 ng/Kg/min)
Study: 8556228
Drug: UFT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT therapy alone
Study: 8556228
Drug: UFT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT therapy in combination with Bestatin
Study: 6372066
Drug: Cimetidine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1 g/day
Study: 7034155
Drug: Antacid/anticholinergic (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid/anticholinergic (10 ml of antacid suspension and 0.6 mg L-hyoscyamine twice a day)
Study: 7034155
Drug: Antacid/anticholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid/anticholinergic
Study: 19261173
Drug: Intradermal influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal influenza vaccination
Study: 20372083
Drug: Intradermal microinjection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal microinjection system
Study: 20372083
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular syringe
Study: 18620598
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and Procalcitonin guided diagnostics and treatment of infection
Study: 16093865
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 60 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Study: 16093865
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 36 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Study: 9104690
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy in NC subjects
Study: 1343921
Drug: Oxamniquine, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine, single dosage of 15 mg/kg for adults and 20 mg/kg for children divided in two doses
Study: 1343921
Drug: Praziquantel, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel, single dose of 60 mg/kg
Study: 1343921
Drug: Praziquantel, sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel, sequential doses of 60 mg/kg during 3 days or 30 mg/kg for 6 days
Study: 1343921
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Oxamniquine and Praziquantel)
Study: 3547254
Drug: Fluoromethalone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoromethalone 0.1% suspension (FML)
Study: 3547254
Drug: Higher penetration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher penetration steroids
Study: 9379354
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg)
Study: 18377975
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose, 10 mg daily maintenance)
Study: 18377975
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg daily maintenance)
Study: 16775579
Drug: High soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High soy diet (two daily soy servings)
Study: 17429240
Drug: Combination phototherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination phototherapy (n=15)
Study: 31004470
Drug: Clazosentan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (15 mg/hour for 3 hours) after rifampin (600 mg/100 mL in 30 minutes)
Study: 31004470
Drug: Clazosentan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (15 mg/hour for 3 hours) after placebo
Study: 19816871
Drug: High bolus
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bolus dose tirofiban (25 microg/kg)
Study: 19816871
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline bolus and infusion)
Study: 19816871
Drug: High bolus
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bolus dose tirofiban (25 microg/kg) in patients with diabetes mellitus
Study: 15133532
Drug: RPR749 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR749 (200 mg)
Study: 2680677
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day piretanide
Study: 2680677
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day piretanide
Study: 2680677
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day bendroflumethiazide
Study: 1127136
Drug: naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500 mg/day)
Study: 24947791
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin peglispro (BIL) at doses ranging from 5.1 to 74.1 mU/min
Study: 24947791
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at doses of 20 or 30 mU/m(2)/min
Study: 19321988
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention group A (oral health instructions + extra reminders)
Study: 19321988
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention group B (oral health instructions)
Study: 20534421
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no erythropoietin treatment)
Study: 9631134
Drug: Hydroxyurea (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg twice daily)